STAT+: In restarted study, Solid Bio reports no serious toxicity in Duchenne patient given ‘safer’ gene therapy

Solid Biosciences said Monday that it has restarted a clinical trial involving its experimental gene therapy for Duchenne muscular dystrophy without the serious safety issues that forced the study to shut down in 2019.

The biotech also disclosed for the first time interim results from patients treated before the study was stopped, showing small improvements in muscle and lung function after one year of follow up. 

Continue to STAT+ to read the full story…

STAT+: In restarted study, Solid Bio reports no serious toxicity in Duchenne patient given ‘safer’ gene therapy

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top